Xvivo Perfusion AB (publ)

OM:XVIVO Stock Report

Market Cap: SEK 14.2b

Xvivo Perfusion Valuation

Is XVIVO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of XVIVO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: XVIVO (SEK451.5) is trading below our estimate of fair value (SEK802.91)

Significantly Below Fair Value: XVIVO is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for XVIVO?

Key metric: As XVIVO is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for XVIVO. This is calculated by dividing XVIVO's market cap by their current earnings.
What is XVIVO's PE Ratio?
PE Ratio69.6x
EarningsSEK 204.27m
Market CapSEK 14.22b

Price to Earnings Ratio vs Peers

How does XVIVO's PE Ratio compare to its peers?

The above table shows the PE ratio for XVIVO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average45.5x
SUS Surgical Science Sweden
38.6x36.1%SEK 7.5b
ARJO B Arjo
17.9x25.1%SEK 9.0b
EKTA B Elekta
21.3x17.9%SEK 24.1b
ELOS B Elos Medtech
104.3xn/aSEK 5.7b
XVIVO Xvivo Perfusion
69.6x26.3%SEK 14.2b

Price-To-Earnings vs Peers: XVIVO is expensive based on its Price-To-Earnings Ratio (69.6x) compared to the peer average (45.5x).

Price to Earnings Ratio vs Industry

How does XVIVO's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
XVIVO 69.6xIndustry Avg. 29.5xNo. of Companies7PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: XVIVO is expensive based on its Price-To-Earnings Ratio (69.6x) compared to the European Medical Equipment industry average (29.5x).

Price to Earnings Ratio vs Fair Ratio

What is XVIVO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XVIVO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio69.6x
Fair PE Ratio34.2x

Price-To-Earnings vs Fair Ratio: XVIVO is expensive based on its Price-To-Earnings Ratio (69.6x) compared to the estimated Fair Price-To-Earnings Ratio (34.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst XVIVO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 451.50
SEK 538.17
+19.2%
7.8%SEK 584.00SEK 480.00n/a6
Nov ’25SEK 448.00
SEK 545.67
+21.8%
6.3%SEK 584.00SEK 480.00n/a6
Oct ’25SEK 503.00
SEK 549.00
+9.1%
6.6%SEK 584.00SEK 480.00n/a6
Sep ’25SEK 533.00
SEK 549.00
+3.0%
6.6%SEK 584.00SEK 480.00n/a6
Aug ’25SEK 506.00
SEK 549.00
+8.5%
6.6%SEK 584.00SEK 480.00n/a6
Jul ’25SEK 418.00
SEK 440.00
+5.3%
13.9%SEK 520.00SEK 340.00n/a6
Jun ’25SEK 440.00
SEK 408.00
-7.3%
12.0%SEK 468.00SEK 340.00n/a6
May ’25SEK 379.00
SEK 408.00
+7.7%
12.0%SEK 468.00SEK 340.00n/a6
Apr ’25SEK 275.00
SEK 382.60
+39.1%
9.0%SEK 425.00SEK 340.00n/a5
Mar ’25SEK 280.50
SEK 382.60
+36.4%
9.0%SEK 425.00SEK 340.00n/a5
Feb ’25SEK 284.50
SEK 389.60
+36.9%
7.8%SEK 425.00SEK 340.00n/a5
Jan ’25SEK 329.50
SEK 377.00
+14.4%
16.3%SEK 450.00SEK 280.00n/a5
Dec ’24SEK 273.00
SEK 363.75
+33.2%
17.1%SEK 450.00SEK 280.00n/a4
Nov ’24SEK 231.00
SEK 371.67
+60.9%
18.8%SEK 450.00SEK 280.00SEK 448.003
Oct ’24SEK 274.50
SEK 391.67
+42.7%
11.5%SEK 450.00SEK 340.00SEK 503.003
Sep ’24SEK 289.50
SEK 391.67
+35.3%
11.5%SEK 450.00SEK 340.00SEK 533.003
Aug ’24SEK 323.00
SEK 376.67
+16.6%
7.2%SEK 405.00SEK 340.00SEK 506.003
Jul ’24SEK 303.50
SEK 376.67
+24.1%
7.2%SEK 405.00SEK 340.00SEK 418.003
Jun ’24SEK 286.00
SEK 376.67
+31.7%
7.2%SEK 405.00SEK 340.00SEK 440.003
May ’24SEK 306.00
SEK 370.00
+20.9%
7.2%SEK 405.00SEK 340.00SEK 379.003
Apr ’24SEK 244.00
SEK 354.00
+45.1%
8.7%SEK 385.00SEK 312.00SEK 275.003
Mar ’24SEK 235.00
SEK 365.50
+55.5%
9.1%SEK 400.00SEK 312.00SEK 280.504
Feb ’24SEK 227.50
SEK 365.50
+60.7%
9.1%SEK 400.00SEK 312.00SEK 284.504
Jan ’24SEK 183.00
SEK 357.50
+95.4%
11.3%SEK 400.00SEK 291.00SEK 329.504
Dec ’23SEK 195.60
SEK 357.50
+82.8%
11.3%SEK 400.00SEK 291.00SEK 273.004
Nov ’23SEK 169.80
SEK 366.60
+115.9%
11.1%SEK 403.00SEK 291.00SEK 231.005

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Mentice

SEK 560.0m

Provides endovascular simulation technology solutions in Europe, the Middle East, Africa, Asia, the Asia Pacific region, and the Americas.

MNTC

SEK 21.90

7D

2.8%

1Y

-46.6%

Dignitana

SEK 95.8m

A medical technology company, engages in the development, production, and marketing of medical cooling devices in the United States and internationally.

DIGN

SEK 1.19

7D

3.5%

1Y

-45.9%

Iconovo

SEK 80.5m

Develops and licenses inhalation medications in Sweden.

ICO

SEK 5.06

7D

2.4%

1Y

-45.1%